Form 4: AN2 Therapeutics Director Receives Stock Compensation

Kabeer Aziz, a director at AN2 Therapeutics, received 8,972 shares of common stock as compensation.

Summary

• Kabeer Aziz, a director of AN2 Therapeutics, received 8,972 shares of common stock on December 19, 2024, as part of the company's non-employee director compensation policy.
• These shares were issued in lieu of cash compensation and vest immediately.
• Mr. Aziz also has indirect beneficial ownership of 1,995,958 shares through Adjuvant Global Health Technology Fund, L.P. and 377,542 shares through Adjuvant Global Health Technology Fund DE, L.P.
• Mr. Aziz disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is a normal part of corporate governance. There is no indication of any negative or positive sentiment.

Positives

• The issuance of shares as compensation aligns with the company's non-employee director compensation policy.
• The immediate vesting of shares may incentivize the director.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when there are changes in beneficial ownership by directors or officers. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Stock compensation for directors is a common practice across the biotechnology industry.
• The number of shares issued is not unusual for a company of AN2 Therapeutics' size and stage.

Stakeholder Impact

• The issuance of shares may slightly dilute existing shareholders' ownership.

Key Dates

Keywords

AN2 Therapeutics, stock compensation, director, Kabeer Aziz, beneficial ownership, Adjuvant Global Health Technology Fund, equity